1Staels B,Dallongeville J,Auwerx J. Mechanism of action of fibrates on lipid and lipoprotein metabolism[J].{H}CIRCULATION,1998,(19):2088-2093.
2Keech A,Simes RJ,Barter P. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study):randomised controlled trial[J].{H}LANCET,2005,(9500):1849-1861.
3Willson TM,Brown PJ,Sternbach DD. The PPARs:from orphan receptors to drug discovery[J].{H}Journal of Medicinal Chemistry,2000,(04):527-550.
4Schoonjans K,Staels B,Auwerx J. The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation[J].{H}Biochimica et Biophysica Acta,1996,(02):93-109.
5Zak Z,Gelebart P,Lai R. Fenofibrate induces effective apoptosis in mantle cell lymphoma by inhibiting the TNFalpha/NF-kappaB signaling axis[J].{H}LEUKEMIA,2010,(08):1476-1486.
6Wilk A,Urbanska K,Grabacka M. Fenofibrate-induced nuclear translocation of FoxO3A triggers Bim-mediated apoptosis in glioblastoma cells in vitro[J].{H}CELL CYCLE,2012,(14):2660-2671.
7Zhao H,Zhu C,Qin C. Fenofibrate down-regulates the expressions of androgen receptor (AR) and AR target genes and induces oxidative stress in the prostate cancer cell line LNCaP[J].{H}Biochemical and Biophysical Research Communications,2013,(02):320-325.
8Wybieralska E,Szpak K,Gorecki A. Fenofibrate attenuates contact-stimulated cell motility and gap junctional coupling in DU-145 human prostate cancer cell populations[J].{H}Oncology Reports,2011,(02):447-453.
9Drukala J,Urbanska K,Wilk A. ROS accumulation and IGF-IR inhibition contribute to fenofibrate/PPARalpha-mediated inhibition of glioma cell motility in vitro[J].{H}Molecular Cancer Therapautics,2010.159.
10Scatena R,Bottoni P,Giardina B. Mitochondria,PPARs,and cancer:is receptor-independent action of PPAR agonists a Key[J].PPAR Res,2008.256251.
